The Insys Investor Day will be held at The Pierre in New York City and hosted by members of the Insys senior management team and industry Key Opinion Leaders. Insys will provide insight into its pipeline including the Company’s sublingual spray product candidates, dronabinol oral solution, pharmaceutical cannabinoids, and Subsys®.
The Insys Investor Day is by invitation only for analysts and institutional investors. An RSVP email@example.com is required to attend.
A live webcast of the Insys Investor Day will be available on the Insys website through the “News and Events” page at www.insysrx.com.
A replay of the Insys Investor Day webcast will be available approximately two hours following the completion of the event at the aforementioned URL. The archived webcast will be available for 90 days.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product: Subsys® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® and Syndros® are registered trademarks of Insys Therapeutics, Inc.
Investor Contact: Lisa M. Wilson In-Site Communications, Inc. Phone: 212-452-2793 Email: firstname.lastname@example.org